Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02538315 : Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients
Phase
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Diagnosis of Parkinson's disease based on clinical diagnosis by Neuro-surgeon and/or
Neurologist with specialty in Parkinson's disease

- Must be a resident of Canada

- Able to understand and provide written informed consent

- Referred by a treating physician

- Patients must be able to tolerate the physical/logistical requirements of a
FDOPA-PET/CT scan, including withholding of medication, lying supine for up to 45
minutes, and intravenous cannulation for injection of the study drug

- 18 years and older, with clinical diagnosis of PD (presence of two out of following
three symptoms: bradykinesia, rigidity and resting tremor) as per standard clinical
practice

Exclusion Criteria:

- Medically unstable patients (e.g. acute cardiac or respiratory distress or
hypotensive, etc.)

- Patients who exceed the safe weight limit of the PET/CT bed or who cannot fit through
the PET/CT bore

- Patients who are claustrophobic
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02538315      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740